Skip to content

Canceled by the investigator. Combined multi-omics to explore biomarkers for immunotherapy in advanced gastric cancer

Combined multi-omics to explore biomarkers for immunotherapy in advanced gastric cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400081772
Enrollment
Unknown
Registered
2024-03-11
Start date
2024-04-01
Completion date
Unknown
Last updated
2024-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced gastric cancer

Interventions

Sponsors

Fujian Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. aged 18-75 years with a pathologically and clinically confirmed diagnosis of advanced gastric cancer (stage IV); 2. receive first-line immunocombination chemotherapy; 3. signed informed consent. 4. ECOG physical status score 0-2; 5. have at least one measurable tumour lesion according to RECIST v1.1 criteria; 6. have good organ function and expected survival of =3 months;

Exclusion criteria

Exclusion criteria: 1. Combination of other malignant tumours. 2. other anti-tumour therapy. 3. severe hepatic or renal insufficiency. 4. pregnant or lactating women. 5. non-tumour progression or death from other systemic diseases; 6. combination of severe cirrhosis, active gastrointestinal bleeding, gastrointestinal perforation, autoimmune disease, and other active malignant tumours

Design outcomes

Primary

MeasureTime frame
RECIST evaluation results;

Secondary

MeasureTime frame
Progression-free survival (PFS);Overall survival (OS);

Countries

China

Contacts

Public ContactXiaojie Wang

Fujian Cancer Hospital

fjzlwxj@126.com+86 135 0939 9900

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026